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Tapinarof, a novel, first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor 
(AhR) modulating agent (TAMA), is in clinical development for the treatment of psoriasis and 
atopic dermatitis. The efficacy of tapinarof in psoriasis is attributed to its specific binding and 
activation of AhR, a ligand-dependent transcription factor, leading to the downregulation of 
pro-inflammatory cytokines, including interleukin-17, and regulation of skin barrier protein 
expression to promote skin barrier normalization. AhR signaling regulates gene expression 
in immune cells and skin cells, and has critical roles in the regulation of skin homeostasis. 
Tapinarof-mediated AhR signaling underlies the mechanistic basis for the significant efficacy 
and acceptable tolerability observed in early phase clinical trials of tapinarof cream in the 












Plaque psoriasis is a common, chronic, immune-mediated disease characterized by scaly, 
erythematous and pruritic well-demarcated lesions that can be painful and disfiguring.1, 2 The 
burden of psoriasis is reported to be similar to that of other chronic conditions, such as 
congestive cardiac failure and chronic lung disease, and includes significant physical, 
psychological, and socioeconomic burdens.3-6 People with psoriasis are at increased risk of 
anxiety and depression,7-9 and experience an increased incidence of several comorbidities.3, 
10-12 
While the introduction of biologics and systemic agents targeting key immune pathways, 
such as the interleukin (IL)-23/IL-17 axis, has significantly advanced treatment particularly of 
more severe disease, conventional topical treatments are used by the vast majority of 
patients with psoriasis.1, 13, 14 Topical agents forming the mainstay of psoriasis treatment 
include corticosteroids, vitamin D derivatives (calcipotriene, calcitriol), vitamin A derivatives 
(tazarotene), anthralin, and coal tar,15 with topical corticosteroids and vitamin D derivatives 
being the most frequently prescribed.16 While efficacious, topical corticosteroids have 
restrictions regarding duration, location, and extent of use. The effectiveness of 
corticosteroids may also be limited by the potential for tachyphylaxis, and recurrence of 
symptoms associated with reduced frequency or cessation of treatment.16 Other topical 
agents, such as calcipotriene and tazarotene, have well-documented adverse events, such 
as skin irritation.15, 17 Considering the importance of topical agents in psoriasis, few options 
with novel mechanisms have been introduced in recent years, and the need for more 
effective and well-tolerated topical therapies remains (Table I).  
Tapinarof is a novel, first-in-class, small molecule topical therapeutic aryl hydrocarbon 
receptor (AhR) modulating agent (TAMA) currently in late-stage clinical trials for the 
treatment of psoriasis and atopic dermatitis. Here, the unique mechanism of action of 










understanding of AhR signaling in the skin and a growing body of clinical trials evidence on 
the efficacy and safety of tapinarof cream in psoriasis18, 19 and atopic dermatitis.20-22 
THE ARYL HYDROCARBON RECEPTOR 
AhR is a ligand-dependent transcription factor 
AhR is a ligand-dependent transcription factor that regulates gene expression in a range of 
cells, including immune and epithelial cells. In healthy skin, AhR signaling plays an integral 
part in maintaining skin homeostasis by regulating the skin immune network, keratinocyte 
differentiation, skin barrier function and pigmentation, and responses to oxidative stress.23, 24 
AhR is crucial to maintaining homeostasis by mediating responses to xenobiotic and 
environmental challenges and is activated by a wide range of low molecular weight ligands 
found in endogenous, dietary, environmental, and microbial sources.23, 25, 26 Endogenous 
AhR ligands include indigoids, heme metabolites, and arachidonic acid metabolites. Dietary 
AhR ligands include flavonoids, carotenoids, and metabolites of commensal gut bacteria,26 
while environmental ligands include polycyclic aromatic hydrocarbons and polychlorinated-
biphenyls.27  
An important characteristic of AhR is its differential activation by this wide range of ligands. 
Upon ligand binding in the cytoplasm, the activated AhR-ligand complex heterodimerizes 
with the AhR nuclear translocator (ARNT), resulting in transformation of the complex into a 
high-affinity DNA-binding transcription factor. The AhR-ligand/ARNT complex binds to 
specific DNA recognition sites, resulting in transcriptional control of AhR-responsive 
genes.28, 29 In addition to its direct effect on gene transcription, AhR can signal through other 
transcription factors, such as nuclear factor kappa-B and nuclear factor erythroid 2-related 
factor 2 (Nrf2), to modulate gene expression.28-30 Thus, depending on the specific ligand, 
binding to AhR can result in induction or repression of different genes, causing diverse 










How different ligands activate AhR to cause such diverse responses has been an area of 
research for numerous years. While the diverse molecular mechanisms of AhR binding and 
downstream signaling remain to be fully elucidated, its therapeutic potential in skin disease 
has become a focus of attention given growing evidence for the essential role of AhR 
signaling in regulating inflammatory responses and skin homeostasis.31-33 
AhR signaling and psoriasis  
AhR is widely expressed in immune cells, including antigen-presenting cells, T cells, 
fibroblasts, macrophages, mast cells, and other skin immune cells, with the expression of 
AhR being necessary for the functioning of antigen-presenting cells, including Langerhans 
cells, and cytokine expression.23 AhR signaling has been shown to regulate the terminal 
differentiation of CD4+ T helper (Th)17 and Th22 cells, as well as the expression of IL-17 
and IL-22 cytokines.32, 34  
AhR is expressed in keratinocytes, and AhR signaling regulates keratinocyte terminal 
differentiation, promotes skin barrier integrity, and prevents trans-epidermal water loss.35, 36 
To maintain skin barrier integrity, AhR activation and signaling has been shown to 
upregulate barrier protein gene expression, including filaggrin.28 Additionally, AhR-mediated 
activation of transcription factors such as Nrf2 induce cytoprotective antioxidant responses 
that suppress oxidative stress and restore skin homeostasis.24, 28  
The contribution of aberrant immune responses to the pathogenesis of psoriasis is well 
established and supported by the demonstrated efficacy and approval of biologics that 
selectively target cytokines, such as tumor necrosis factor α, IL-23, and IL-17A.14 The 
immune response in psoriasis is characterized by increased skin infiltration and activation of 
effector CD4+ T cells, including the upregulation of Th17 and Th22 cells.37, 38 Crosstalk 
between immune cells and skin cells contributes to the formation and exacerbation of 
psoriatic plaques and, histologically, psoriasis is characterized by aberrant differentiation and 
hyperproliferation of keratinocytes in the upper layers of the epidermis.2 Further, in psoriasis, 









with downregulation of skin barrier protein expression, including filaggrin and loricrin.39 
Oxidative stress has also been implicated in the pathogenesis of psoriasis, through a 
pathogenic effect that results in cellular damage, inflammation, and impairment of skin 
barrier function.40-42 
Current understanding of the expression and function of AhR in the skin supports further 
investigation into AhR signaling as a therapeutic target in psoriasis and other inflammatory 
skin diseases. Non-specific modulation of AhR signaling possibly underlies the mechanism 
of action of coal tar, one of the oldest topical treatments in psoriasis, which contains a 
mixture of organic compounds including polycyclic aryl hydrocarbons that may activate AhR 
to exert a therapeutic effect.43, 44 
A potential functional role of AhR in psoriasis has been demonstrated in AhR-deficient mice 
that developed exacerbated psoriasiform skin inflammation with increased IL-17 and IL-22 
expression in an imiquimod-induced psoriasis model. Additionally, treatment of wild-type 
mice with 6-formylindolo[3,2-b]carbazole, an endogenous AhR ligand found in skin, 
ameliorated psoriasiform skin inflammation and pathology in an imiquimod-induced psoriasis 
model.45 
In patients with psoriasis, dysregulated AhR expression has been demonstrated. Increased 
serum levels of AhR were identified in patients with psoriasis compared with healthy 
subjects.46 Increased AhR expression in peripheral blood mononuclear cells of patients with 
psoriasis was associated with increased Th22 cells and IL-22 expression compared with 
healthy subjects.47 Increased AhR expression has been identified in skin biopsies of patients 
with psoriasis,48 and treatment of skin cells with AhR ligands in vitro resulted in the 
modulation of genes implicated in the pathogenesis of psoriasis, including IL-6, IL-8, and 
type I and II interferon pathway genes.45, 48 
Taken together, these findings suggest that AhR ligation may modulate downstream effector 









psoriasis. The specific binding and activation of AhR by tapinarof leads to the modulation of 
a unique set of target genes that are dysregulated in psoriasis and includes IL-17, thus 
exerting therapeutic effects that are distinct from other AhR ligands.49 This is significant 
because the activity of AhR is highly ligand-dependent, and several naturally occurring and 
synthetic AhR ligands are known to exert differential biologic effects via the AhR 
transcription factor and downstream pathways.23 
TAPINAROF AS A TREATMENT FOR PSORIASIS 
Tapinarof discovery 
The discovery of tapinarof (DMVT-505; previously known as WBI-1001 and GSK2894512) 
was a fortuitous outcome of investigations into the secondary metabolites of Photorhabdus 
luminescens, a bioluminescent, gram-negative bacillus, which lives symbiotically within 
parasitic, soil-living entomopathogenic nematodes of the genus Heterorhabditis.50, 51 P. 
luminescens is essential to the reproduction of the nematode, as the worm carries the 
symbiont in its intestines and, upon entering a host insect, releases the bacilli, which help to 
preserve insect tissue in optimal conditions for nematode growth.51, 52  
In 1959, Dutky first noted that insects infected by the nematode did not putrefy once dead, in 
contrast to the rapid decay seen in the absence of the nematode.53 It was therefore 
postulated that P. luminescens was producing metabolites with antimicrobial and other 
properties responsible for the observed biologic effect. One such metabolite was purified and 
identified as 3,5-dihydroxy-4-isopropylstilbene, a small molecule with a low molecular weight 
(254 g/mol).51, 54 Pharmaceutical development of 3,5-dihydroxy-4-isopropylstilbene 
(tapinarof) identified the compound to have anti-inflammatory properties.55 The mechanism 
of action of tapinarof was elucidated by profiling against more than 800 potential cellular 
targets, including a diverse array of kinases and other intracellular enzymes, nuclear 
receptors, transcription factors, and mediators of epigenetic signaling, where the most potent 










in downregulation of inflammatory cytokines, regulation of skin barrier protein expression, 
and antioxidant activity.33, 49  
Tapinarof-modulated AhR signaling in immunomodulation  
One of the proposed mechanisms for the observed clinical effect of tapinarof in patients with 
psoriasis is via the suppression of key Th17/Th22 cytokines, IL-17, and IL-22. In a T-cell 
polarization assay, tapinarof markedly inhibited T-cell expansion and Th17-cell 
differentiation, and reduced the production of IL-17,33 while also reducing IL-17A and IL-17F 
levels in a CD4+ T-cell assay.33 In a mouse model of psoriasis, tapinarof treatment 
downregulated inflammatory cytokine expression in skin tissue, including IL17A, IL17F, IL19, 
IL22, IL23A, and IL1β gene expression.33 The downregulation of cytokines by tapinarof was 
not observed in AhR-deficient mice, supporting the conclusion that tapinarof has an anti-
inflammatory role mediated via AhR signaling in vivo.33 
Tapinarof-modulated AhR signaling in regulating keratinocyte function  
The regulation of skin barrier protein expression and normalization of skin cell differentiation 
via modulation of the AhR signaling pathway both provide a mechanistic rationale for the 
therapeutic effects of tapinarof observed in clinical trials of psoriasis and atopic dermatitis.18, 
21 Tapinarof has been shown to induce expression of skin barrier genes related to 
keratinocyte differentiation33 that are downregulated in psoriasis, including filaggrin and 
loricrin.56 The role of tapinarof in restoring epidermal function to promote normalization of 
skin barrier mechanisms is also supported by the finding that AhR-deficient keratinocytes are 
hyper-responsive to pro-inflammatory cytokines, exhibit increased production of 
inflammatory mediators, and develop psoriatic pathology.57, 58 
Tapinarof-modulated AhR signaling in reduction of oxidative stress 
In patients with psoriasis, increased circulating reactive oxygen species (ROS) and 
decreased antioxidant levels are associated with increased disease severity.59 Tapinarof is a 
stilbene molecule containing two phenol groups that directly scavenge ROS, including 









Tapinarof also induces the AhR-Nrf2 transcription factor pathway leading to expression of 
antioxidant enzyme genes, such as NAD(P)H, quinone oxidoreductase 1, and heme 
oxygenase‐1, to reduce ROS.24, 33 AhR-mediated antioxidant activity and subsequent ROS 
reduction has been demonstrated to reduce inflammatory responses, including decreasing 
keratinocyte IL-8 expression.60 Thus, the combined antioxidant response through the Nrf2 
pathway and direct ROS scavenging by tapinarof may together reduce epidermal oxidative 
stress known to cause significant cellular damage to skin in the pathogenesis of psoriasis.  
Tapinarof in psoriasis clinical trials 
Initial clinical proof-of-concept studies were conducted using a different formulation of 
tapinarof cream, WBI-1001. A phase 2 study demonstrated that WBI-1001 1% concentration 
cream applied twice daily (BID) for 12 weeks significantly improved Physician Global 
Assessment (PGA) scores compared with vehicle in patients with mild to moderate plaque 
psoriasis. Adverse drug reactions, mostly at application sites, were more frequent with active 
treatment than with vehicle, but all were mild or moderate in intensity.55 WBI-1001 was later 
reformulated to enhance the drug product’s stability and delivery, resulting in the current 
formulation of tapinarof cream in clinical development, which was evaluated in a phase 2b 
dose-ranging study in patients with mild to severe plaque psoriasis. In this study, patients 
were randomized to tapinarof cream 0.5% or 1% once daily (QD) or BID, or vehicle QD or 
BID for 12 weeks with a 4-week treatment-free follow-up. The primary endpoint was PGA 
score 0 or 1 and ≥2-grade improvement at week 12. The proportion of patients achieving the 
primary endpoint was significantly higher in all tapinarof cream groups than in vehicle groups 
(65% [1%BID], 56% [1%QD], 46% [0.5%BID], and 36% [0.5%QD] versus 11% [vehicle BID] 
and 5% [vehicle QD]), and was maintained for 4 weeks after the end of treatment through 
Week 16 in all tapinarof groups except for the 0.5%BID group. Clinically meaningful 
improvements in psoriasis outcomes were observed as early as 2 weeks of treatment with 
tapinarof cream, and significant improvements were maintained for 4 weeks after treatment 










adverse events were mild or moderate in severity.18 The safety and efficacy of tapinarof 1% 
cream QD is being evaluated in a pivotal phase 3 psoriasis clinical program, which 
comprises two randomized controlled trials in adults with plaque psoriasis, with expected 
completion in 2020 (NCT02564042 and NCT03983980).   
Evidence thus far demonstrates that tapinarof-mediated AhR activation has the potential to 
exert multiple mechanistic effects in psoriasis from immune modulation to the regulation of 
skin barrier function, which is supported by the potential of AhR to control gene transcription 
directly or indirectly through other transcription factors, and its wide expression in different 
cell types and tissues (Fig 1). In psoriasis, the totality of in vitro, ex vivo, and in vivo data 
support an anti-inflammatory mechanism in which tapinarof/AhR/ARNT complexes directly 
bind to the IL17A promotor and suppress IL17A transcription. Additionally, the observation 
that methylation of the IL17A promoter is increased in response to tapinarof provides further 
support for an anti-inflammatory effect mediated by decreased expression of IL-17A upon 
treatment (Dermavant Sciences, Inc. Unpublished data); the latter epigenetic modification of 
the IL17A promoter may explain, in part, the durability of therapeutic effect in the phase 2b 
clinical trial where significant improvements were maintained for 4 weeks after 
discontinuation of tapinarof in patients with psoriasis.18 
Further studies will contribute to a more precise mechanistic understanding of how AhR 
activation by tapinarof leads to downstream effector functions and is an opportunity for future 
study with tapinarof cream to further support the translation of its mechanistic effects to 
clinical outcomes in patients with psoriasis.  
CONCLUSIONS  
The efficacy of tapinarof in psoriasis is attributed to its activation of AhR, a ligand-dependent 
transcription factor, which modulates gene expression of IL-17 and skin barrier proteins to 
exert an anti-inflammatory effect and promote skin barrier normalization, respectively, in 









unique biologic outcomes that manifest clinically as significant therapeutic efficacy for a 
topical agent in the treatment of inflammatory skin diseases.61 Tapinarof has been effective 
and generally well tolerated in clinical trials to date, and the positive phase 2 findings have 
led to progression to a pivotal phase 3 clinical trial program. Further data from those clinical 
trials will provide a greater understanding of the benefits and safety and tolerability profile of 
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AhR: aryl hydrocarbon receptor 
ARNT: AhR nuclear translocator 
BID: twice daily 
IL: interleukin 
Nrf2: nuclear factor erythroid 2-related factor 2  
PGA: Physician Global Assessment 
QD: once daily  
ROS: reactive oxygen species  
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Fig 1. Potential mechanisms of action of tapinarof in the treatment of psoriasis.  
Tapinarof activation of the aryl hydrocarbon receptor modulates gene expression that leads 
to significant reduction of Th17 cytokines implicated in plaque psoriasis, including IL-17A 
and IL-17F*†‡; increase in antioxidant response through the Nrf2 pathway, as well as direct 
ROS scavenging by tapinarof*†; and regulation of skin barrier protein expression, including 
filaggrin and loricrin.*  
*Demonstrated in vitro. †Demonstrated ex vivo; ‡Demonstrated in mouse models.  
AhR, Aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor nuclear translocator; 
FLG, filaggrin; IL, interleukin; LOR, loricrin; Nrf2, nuclear factor erythroid 2-related factor 2; 











Table I: Tapinarof* and FDA-approved topical monotherapy for the treatment of plaque psoriasis  
Active principle,  
vehicle, concentration,  
dosing frequency,  
FDA plaque 
psoriasis indication, 
initial approval year  
Efficacy outcomes and duration of 
response/follow-up; active vs vehicle 
Duration of use Common adverse events (≥1%) 
Corticosteroids 
Clobetasol propionate 
- 0.05% spray BID62  
 
• Plaque psoriasis  
• Moderate-severe, 
affecting ≤20% BSA 
• Age ≥18 years  
• 1985 
 
• Week 2, IGA = 0/1: 47–55% vs 0–2% 
• PASI = NA 
• Follow-up = NA 
 
 
• ≤4 weeks; >2 weeks is 
limited to localized 
moderate/severe 
lesions that insufficiently 
improve  
 
• Application site: burning (40%), pruritus (3%), dryness 
(2%), irritation (1%), pain (1%), pigmentation changes 
(1%) 
• URTI (8%) 
• Nasopharyngitis (5%)  
• Pharyngitis streptococcal (1%) 
- 0.025% cream BID63  • Plaque psoriasis  
• Moderate-severe 
• Age ≥18 years 
• 1985 
 
• Week 2, IGA = 0/1+≥2-GI: 30% vs 9–10%  
• PASI = NA 
• Follow-up = NA 
 
• ≤2 weeks 
 
 
• Application-site discoloration (2%) 
Halobetasol propionate  
- 0.05% lotion BID64  
 
 
• Plaque psoriasis  
• Age ≥18 years 
• 1990 
 
• Week 2, IGA = 0/1+≥2-GI: 45% vs 6–7% 
• PASI = NA 
• Follow-up = NA 
 
• ≤2 weeks 
 
• Application-site atrophy (1%) 
• Telangiectasia (1%) 
• Headache (1%) 
- 0.01% lotion QD65 
 
• Plaque psoriasis  
• Age ≥18 years  
• 1990 
• Week 8, IGA = 0/1+≥2-GI: 37–38% vs 8–12%  
• PASI = NA 
• Follow-up = ≤12 weeks (4 weeks after stopping 
therapy) superior to vehicle   
• ≤8 weeks • URTI (2%) 
• Application-site dermatitis (1%) 
• Hyperglycemia (1%) 
Desoximetasone  
- 0.25% spray BID66  
 
• Plaque psoriasis  
• Age ≥18 years 
• 1977 
 
• Week 4, PGA=0/1: 31–53% vs 5–18% 
• PASI = NA 
• Follow-up = NA 
 
 









- 0.05% spray BID67  
 
• Plaque psoriasis  
• Mild-moderate 
• Age ≥18 years 
• 1975 
 
• Week 2, IGA = 0/1+≥2-GI: 19–22% vs 2–7%  
• PASI = NA 
• Follow-up = NA 
 
 





• Application site: pruritus (6%), burning/stinging 
(4.5%), pain (2.3%), atrophy (1.1%) 
Vitamin D analogs 
Calcitriol 




• Plaque psoriasis  
• Mild-moderate 




• Week 8, IGA = 0/1+≥2-GI: 21–23% vs 7–14% 
• PASI = NA 
• Follow-up = NA 
 
 





• Hypercalcemia (24%) 
• Lab test abnormality (8%) 
• Hypercalciuria (3%) 
• Skin discomfort (3%) 
• Pruritus (1–3%) 










• Psoriasis (4%) 
Calcipotriene 
- 0.005% foam BID69 
 
• Plaque psoriasis  
• Age ≥18 years  
• 1993 
 
• Week 8, ISGA = 0/1+≥2-GI: 14–27% vs 7–16% 
• PASI = NA 
• Follow-up = NA 
 
• ≤8 weeks 
 
• Application site: pain (3%), erythema (2%) 
- 0.005% cream BID70 
 
• Plaque psoriasis  
• Age ≥18 years  
• 1997 
• Week 8, 50% at least marked improvement; 4% 
complete clearing; vehicle NA  
• PASI = NA 
• Follow-up = NA 
• ≤8 weeks • Skin irritation (10–15%) 








• Plaque psoriasis 
• Affecting ≤20% 
BSA 
• Age ≥12 years  
• 1997 
 
• Week 12, overall lesional assessment of none, 
minimal, or mild: 39–51% vs 24–26%  
• PASI = NA 
• Superiority over vehicle as early as Week 1 or 2 
for 0.1% or 0.05% cream QD, respectively 
• Follow-up = ≤24 weeks (12 weeks after stopping 
therapy) superior to vehicle  
 
• ≤12 weeks 
 
 
• Pruritus, erythema, and burning (10–23%) 
Therapeutic aryl hydrocarbon receptor modulating agents 
Provisional data from one  
Phase 2b trial18, 19, 72 
Tapinarof* 





• Plaque psoriasis 
• Mild-severe 
• Age ≥18 years  
• TBD – pending 
phase 3 data 
 
 
• Week 12, PGA = 0/1+≥2-GI: 56% vs 5% (p<0.05) 
• Week 12, PASI75 = 56% vs 5% (p<0.001)  
• Week 12, PASI90 = 40% vs 0% (p=0.001)  
• PGA and PASI75 responses were observed as 
early as Week 2 and were significantly superior to 
vehicle by Week 8  
• Follow-up = 16 weeks (4 weeks after stopping 








• Contact dermatitis (11%) 
• Folliculitis (5%) 
• Application-site dermatitis (5%) 
• Miliaria (5%) 
• Urticaria (5%) 
• Nasopharyngitis (3%) 
• Headache (3%) 
BID, Twice daily; BSA, body surface area; FDA, Food and Drug Administration; GI, grade improvement; ISGA, Investigator's Static Global Assessment; IGA, Investigator's 
Global Assessment; NA, not available; PASI, Psoriasis Area and Severity Index; PASI75, ≤75% improvement in Psoriasis Area and Severity Index; PASI90, ≤90% 
improvement in Psoriasis Area and Severity Index; PGA, Physician Global Assessment; QD, once daily; TBD, to be decided; URTI, upper respiratory tract infections. 
Table presents registration trial data extracted from FDA labels; comparisons between agents are not recommended in the absence of head-to-head trial data.  
*Tapinarof is an investigational drug, data are from a phase 2b randomized controlled trial.18, 19, 72 Two phase 3 trials, PSOARING 1 (NCT03956355) and PSOARING 2 
(NCT03983980) are expected to report in 2020.  
†Restrictions regarding duration of use with tapinarof are not anticipated; more information will be available following completion of a phase 3 long-term extension trial, 









• Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent 
(TAMA) that downregulates IL-17 and promotes skin barrier normalization, with 
antioxidant activity 
• Efficacy and tolerability of tapinarof in psoriasis clinical trials is attributed to its unique 
mechanism of action, representing an important potential advance in the 
development of topical medicine  
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